In 2023, it is expected that the voice biomarkers market would be worth US$ 2.3 billion. By 2033, it is anticipated to hit US$ 9.1 billion. The demand for vocal biomarkers is anticipated to grow globally between 2023 and 2033 at a CAGR of 14.7%.
Over the next ten years, there will likely be a major increase in the market for voice biomarkers. The increase in neurological, mental, and other language-related diseases may be to blame for this.
Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=719?AS
Market Frontrunners
- Boston Technology Corporation
- EVOCAL Health
- Audio Profiling
- Cogito Corporation
- Kintsugi
- Sharecare Inc.
- Microtest Health
- Sonde Health
- AudEERING
- Beyond Verbal
- IBM Corporation
Key Drivers
- North America is likely to capture a commendable share of the global vocal biomarker market.
- Europe will exhibit strong growth on the back of expanding psychiatrist clinics, presence of leading players, and advancement in medical technology across the U.K. and Germany.
- With increasing prevalence of cardiovascular and psychological disorders and rising government support, Asia is expected to emerge as a lucrative market for vocal biomarkers.
- By indication, psychiatric disorders segment is expected to dominate the vocal biomarker market.
- Hospitals & clinics segment will emerge as the primary end user in the global vocal biomarker market.
- Increasing prevalence of psychological and cardiovascular disorders worldwide is driving the vocal biomarker market.
- Rising need for minimally invasive procedures for diagnosis of various disorders will continue to fuel the demand for vocal biomarkers.
- Low cost, easy availability, and growing awareness regarding the importance of vocal biomarkers will aid the growth in the market during the forecast period.
- Emergence of advanced vocal biomarker screening platforms will facilitate the growth in the market.
Recent Developments
- In August 2022, PureTech Health plc announced that its founding company, Sonde Health has entered into a multi-year agreement with pharmaceutical company Koye Pharmaceuticals. This agreement will help the company to develop novel voice biomarker detection and monitoring capabilities for chronic obstructive pulmonary disease (COPD) in India.
- In August 2022, Ellipsis Health and Ceras Health, a leading digital health solutions company, joined hands to accelerate the former’s discovery in using the human voice as a mental biomarker.
Segment Insights
With the modern study, Fact.MR provides an unbiased analysis of the global vocal biomarker market over the forecast period (2023 to 2033). The study also provides a comprehensive analysis of key trends, opportunities, and drivers driving the sales of vocal biomarkers through detailed segmentation as follows:
Technique:
- Frequency
- Amplitude
- Error Rate
- Vocal Rise or Fall Time
- Phonation Time
- Vocal Tremor
- Pitch
- Others
Indication:
- Psychiatric Disorders
- Respiratory Disorders
- Cardiovascular Disorders
- Traumatic Brain Injury (TBI)
- Neurological disorders
- Other
End User:
- Hospitals & Clinics
- Contract Research Organizations CROs)
- Academic & Research Centers
- Other End Users
Region:
- North America
- Latin America
- Europe
- Asia and Pacific
- The Middle East and Africa
Key Questions Covered in the Vocal Biomarker Market Report
- How will the demand for vocal biomarkers surge during the forecast period?
- Which are the key trends propelling the sales of a vocal biomarker in the market?
- Which region will be the most lucrative in the vocal biomarker market from 2023 to 2033?
- What is the projected market valuation of the vocal biomarker market in 2033?
- What are the challenges vocal biomarker providers might face over the upcoming decade?
- Which will be the leading end users in the vocal biomarker market?
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=719?AS
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Email : sales@factmr.com